These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21477408)

  • 21. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild Alzheimer's disease: a pilot study.
    Buschert VC; Friese U; Teipel SJ; Schneider P; Merensky W; Rujescu D; Möller HJ; Hampel H; Buerger K
    J Alzheimers Dis; 2011; 25(4):679-94. PubMed ID: 21483095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC; Hirni DI; Taylor KI; Berres M; Regeniter A; Gass A; Monsch AU; Sollberger M
    J Alzheimers Dis; 2015; 44(2):625-33. PubMed ID: 25322924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020.
    Hampel H; Lista S; Teipel SJ; Garaci F; Nisticò R; Blennow K; Zetterberg H; Bertram L; Duyckaerts C; Bakardjian H; Drzezga A; Colliot O; Epelbaum S; Broich K; Lehéricy S; Brice A; Khachaturian ZS; Aisen PS; Dubois B
    Biochem Pharmacol; 2014 Apr; 88(4):426-49. PubMed ID: 24275164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Awareness disorders in Alzheimer's disease and in mild cognitive impairment].
    Jacus JP; Dupont MP; Herades Y; Pelix C; Large H; Baud M
    Encephale; 2014 Apr; 40(2):180-7. PubMed ID: 24630532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force.
    Cummings J; Fox N; Vellas B; Aisen P; Shan G
    J Prev Alzheimers Dis; 2018; 5(2):103-109. PubMed ID: 29616703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in the therapy of Alzheimer's disease: targeting amyloid beta and tau and perspectives for the future.
    Hampel H; Schneider LS; Giacobini E; Kivipelto M; Sindi S; Dubois B; Broich K; Nisticò R; Aisen PS; Lista S
    Expert Rev Neurother; 2015 Jan; 15(1):83-105. PubMed ID: 25537424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Screening and treatment for Alzheimer's disease: predicting population-level outcomes.
    Furiak NM; Kahle-Wrobleski K; Callahan C; Klein TM; Klein RW; Siemers ER
    Alzheimers Dement; 2012 Jan; 8(1):31-8. PubMed ID: 22265589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers in Alzheimer's disease: not yet surrogate endpoints.
    Coley N; Andrieu S; Delrieu J; Voisin T; Vellas B
    Ann N Y Acad Sci; 2009 Oct; 1180():119-24. PubMed ID: 19906266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives.
    Wang J; Tan L; Yu JT
    J Alzheimers Dis; 2016; 50(4):927-45. PubMed ID: 26836177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
    Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
    Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome measures in clinical trials on medicinal products for the treatment of dementia: a European regulatory perspective.
    Broich K
    Int Psychogeriatr; 2007 Jun; 19(3):509-24. PubMed ID: 17433121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?
    Messner DA; Rabins P; Downing AC; Irizarry M; Foster NL; Al Naber J; Dabbous O; Fillit H; Gabler S; Krakauer R; Lotz D; Payzant E; Schneider L; Tyrone J; Van Amerongen D; Wuest D
    J Prev Alzheimers Dis; 2019; 6(1):20-26. PubMed ID: 30569082
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions.
    Andrieu S; Coley N; Lovestone S; Aisen PS; Vellas B
    Lancet Neurol; 2015 Sep; 14(9):926-944. PubMed ID: 26213339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statistical analysis, trial design and duration in Alzheimer's disease clinical trials: a review.
    Thompson PA; Wright DE; Counsell CE; Zajicek J
    Int Psychogeriatr; 2012 May; 24(5):689-97. PubMed ID: 21910950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current Clinical Trials in the Treatment of Alzheimer's Disease].
    Tamaoka A
    Brain Nerve; 2020 Jan; 72(1):23-34. PubMed ID: 31907330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of functional tasks exercise on older adults with cognitive impairment at risk of Alzheimer's disease: a randomised controlled trial.
    Law LL; Barnett F; Yau MK; Gray MA
    Age Ageing; 2014 Nov; 43(6):813-20. PubMed ID: 24850540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Neuropsychological Perspective on Defining Cognitive Impairment in the Clinical Study of Alzheimer's Disease: Towards a More Continuous Approach.
    Jutten RJ; Thompson L; Sikkes SAM; Maruff P; Molinuevo JL; Zetterberg H; Alber J; Faust D; Gauthier S; Gold M; Harrison J; Lee AKW; Snyder PJ
    J Alzheimers Dis; 2022; 86(2):511-524. PubMed ID: 35124638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.